Clofarabine. Bioenvision/ILEX.
Clofarabine is a purine nucleoside antimetabolite under development by Bioenvision (under license from the Southern Research Institute) and ILEX for the potential treatment of solid tumors, acute myelogenous leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic and chronic lymphocytic leukemia. In September 2003, Bioenvision initiated a phase II trial in Europe in pediatric acute lymphoblastic leukemia, and in October 2003, ILEX submitted the first part of a rolling NDA to the FDA for the treatment of acute leukemia in children.
Sternberg
Alexander
A
Academic Department of Haematology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK. stern@molbiol.ox.ac.uk
D000227:Adenine Nucleotides; D000818:Animals; D001087:Arabinonucleosides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D000077866:Clofarabine; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods
D000227:Adenine Nucleotides; D001087:Arabinonucleosides; D015507:Drugs, Investigational; D000077866:Clofarabine